In­novent bets $250M+ on Union's PDE4 in­hibitor ahead of a PhII read­out

A year af­ter pluck­ing oris­mi­last from Leo Phar­ma­ceu­ti­cals’ pipeline — and with­out pub­lish­ing any mid-stage da­ta — Union Ther­a­peu­tics is al­ready mak­ing a pret­ty pen­ny on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER